Skip to main content

Advertisement

SpringerLink
Log in

Relationship between management of hyperthyroidism and course of the ophthalmopathy

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The relationship between treatment for hyperthyroidism and course of Graves’ ophthalmopathy (GO) has been and still is a matter of debate. Literature often presents conflicting data, due to several influencing factors, such as selection bias, nonrandomized and uncontrolled or retrospective features of many studies, non-standardized evaluation of ocular changes. However, it seems clear that neither antithyroid drug treatment nor thyroidectomy affect the natural course of GO, while radioiodine therapy may cause, in about 15% of cases, GO progression. The latter is more likely in patients who smoke, have pre-existing GO and more severe hyperthyroidism, or whose post-radioiodine hypothyroidism is not promptly corrected by L-thyroxine. GO progression after radioiodine therapy can be prevented by concomitantly treating patients with glucocorticoids, thus making radioiodine therapy a safe procedure also in GO patients. The presence of GO should not, therefore, influence the choice of treatment for hyperthyroidism. Should antithyroid drug treatment or thyroidectomy be selected for patients with mild ophthalmopathy, no treatment for GO is necessary, while a short course of moderate doses of glucocorticoids is advised if radioiodine therapy is chosen. In patients with severe GO, treatment of hyperthyroidism and management of GO proceed independently of each other, and either definitive (radioiodine or thyroidectomy) or conservative (antithyroid drugs) treatment for hyperthyroidism can be selected while treating GO. The authors’ preference goes to the former, because it depletes intrathyroidal autoreactive T lymphocytes and removes thyroid antigens, which are likely to be involved in the pathogenesis of autoimmune reactions of the ophthalmopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.

    PubMed  CAS  Google Scholar 

  2. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 1989, 120:473–8.

    Google Scholar 

  3. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1995, 42: 42–50.

    Article  Google Scholar 

  4. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves’ ophthalmopathy and type of treatment of Graves’ hyperthyroidism. Thyroid 1992, 2: 171–8.

    Article  PubMed  CAS  Google Scholar 

  5. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990, 70: 1518–24.

    Article  PubMed  CAS  Google Scholar 

  6. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 1997, 7: 369–75.

    Article  PubMed  CAS  Google Scholar 

  7. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibody to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991, 324: 947–53.

    Article  PubMed  CAS  Google Scholar 

  8. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996, 334: 220–4.

    Article  PubMed  CAS  Google Scholar 

  9. Glinoer D, de Nayer P, Bex M, and the Belgian Collaborative Group on Graves’ Disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ disease treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001, 144: 475–93.

    Article  PubMed  CAS  Google Scholar 

  10. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989, 121 (Suppl. 2): 185–9.

    Google Scholar 

  11. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 1990, 150, 1098–101.

    Article  PubMed  CAS  Google Scholar 

  12. Solem JH, Segaard E, Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand 1979, 205: 111–4.

    Article  PubMed  CAS  Google Scholar 

  13. Aranow H Jr, Day RM. Management of thyrotoxicosis in patients with ophthalmopathy: antithyroid regimen determined primarily by ocular manifestations. J Clin Endocrinol Metab 1965, 25: 1–10.

    Article  PubMed  Google Scholar 

  14. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998, 338: 73–8.

    Article  PubMed  CAS  Google Scholar 

  15. Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves’ disease. JAMA 1982, 247: 2136–8.

    Article  Google Scholar 

  16. Marcocci C, Bartalena L, Pinchera A. Ablative or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 468–71.

    Article  PubMed  CAS  Google Scholar 

  17. Weetman AP, Harrison BJ. Ablative or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 472–5.

    Article  PubMed  CAS  Google Scholar 

  18. Catz B, Perzik SL. Subtotal vs total surgical ablation of the thyroid, malignant exophthalmos and its relation to remnant thyroid. In: Cassano C, Andreoli M eds. Current topics in thyroid research. New York: Academic Press. 1983, 1183–8.

    Google Scholar 

  19. Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery 1996, 120: 1020–4.

    Article  PubMed  CAS  Google Scholar 

  20. Fernandez-Sanchez JR, Rosell Pradas J, Carazo Martinez O, et al. Graves’ ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg 1993, 80: 1134–6.

    Article  PubMed  CAS  Google Scholar 

  21. Patwardhan NA, Moront M, Rao S, Rossi S, Braverman LE. Surgery still has a role in Graves’ hyperthyroidism. Surgery 1993, 114: 1108–13.

    PubMed  CAS  Google Scholar 

  22. Abe Y, Sato H, Noguchi M, et al. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves’ disease. World J Surg 1998, 22: 714–7.

    Article  PubMed  CAS  Google Scholar 

  23. Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med 1989, 87: 70–3.

    Article  PubMed  CAS  Google Scholar 

  24. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992, 326: 1733–8.

    Article  PubMed  CAS  Google Scholar 

  25. Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves’ ophthalmopathy is not influenced by near-total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999, 51: 503–8.

    Article  CAS  Google Scholar 

  26. Bartalena L, Marcocci C, Pinchera A. Radioiodine therapy and Graves’ ophthalmopathy. In: Rapoport B, McLachlan SM eds. Graves’ Disease: pathogenesis and treatment. Boston: Kluwer Academic Publishers. 2000, 279–92.

    Chapter  Google Scholar 

  27. Gorman CA. Radioiodine therapy does not aggravate Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995, 80: 340–2.

    Article  PubMed  CAS  Google Scholar 

  28. Pinchera A, Bartalena L, Marcocci C. Radioiodine may be bad for Graves’ ophthalmopathy, but…. J Clin Endocrinol Metab 1995, 80: 342–5.

    Article  PubMed  CAS  Google Scholar 

  29. Werner SC, Coelho B, Quimby EH. Ten year results of I-131 therapy in hyperthyroidism. Bull NY Acad Sci 1957, 33: 783–806.

    CAS  Google Scholar 

  30. Hamilton HE, Schutz RO, De Gowil EL. The endocrine eye lesion in hyperthyroidism. Arch Intern Med 1960, 105: 675–85.

    Article  PubMed  CAS  Google Scholar 

  31. Hamilton RD, Mayberry VE, McConahey WM, Hanson KC. Ophthalmopathy of Graves’ disease: a comparison between patients treated surgically and patients treated with radioiodine. Mayo Clin Proc 1967, 42: 812–8.

    PubMed  CAS  Google Scholar 

  32. Pequegnat EP, Mayberry WE, McConahey WM, Wyse EP. Large doses of radioiodine in Graves’ disease: effects on ophthalmopathy and long-acting thyroid stimulator. Mayo Clin Proc 1967, 42: 802–11.

    PubMed  CAS  Google Scholar 

  33. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger RD. Studies on the pathogenesis of the ophthalmopathy of Graves’ disease. J Clin Endocrinol Metab 1967, 27: 582–93.

    Article  PubMed  CAS  Google Scholar 

  34. Hetzel BS, Mason EK, Kwan WH. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis. Australas Ann Med 1967, 17: 307–11.

    Google Scholar 

  35. Aron-Rosa D, Pérez R, Abitbol Y. Malignant exophthalmos after iodine-131 treatment. Mod Probl Ophthalmol 1973, 14: 432–4.

    Google Scholar 

  36. Calissendorf BM, Soderstrom M, Alveryd A Ophthalmopathy and hyperthyroidism: a comparison between patients receiving different antithyroid treatments. Acta Ophthalmol 1986, 64: 698–703.

    Article  Google Scholar 

  37. Vestergaard H, Laurberg P. Radioiodine and aggravation of ophthalmopathy. Lancet 1989, 2: 47.

    Article  PubMed  CAS  Google Scholar 

  38. Barth A, Probst P, Burgi H. Identification of a subgroup of Graves’ disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 1989, 14: 209–12.

    Article  Google Scholar 

  39. Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994, 79: 542–6.

    PubMed  CAS  Google Scholar 

  40. Manso PG, Furlanetto RP, Wolosker AMB, Paiva ER, de Abreu MT, Maciel RMB. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves’ hyperthyroidism. Thyroid 1998, 8: 49–52.

    Article  PubMed  CAS  Google Scholar 

  41. Spitzweg C, Rossmuller B, Heufelder AE. Radioiodine therapy and Graves’ ophthalmopathy. Thyroid 1998, 8: 1193.

    Article  PubMed  CAS  Google Scholar 

  42. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989, 321: 1349–52.

    Article  PubMed  CAS  Google Scholar 

  43. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994, 130: 494–7.

    Article  PubMed  CAS  Google Scholar 

  44. Vàzquez-Chàvez C, Nishimura Megura E, Espinosa Said L, Delgado Falfari A, Sàinz de Viteri M. Influencia del tratamento del hipertiroidismo en el curso del exoftalmos. Rev Invest Clin 1992, 44: 241–7.

    PubMed  Google Scholar 

  45. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998, 129: 632–5.

    Article  PubMed  CAS  Google Scholar 

  46. Bartalena L. Smoking and Graves’ disease. J Endocrinol Invest 2002, 25: 402.

    Article  PubMed  Google Scholar 

  47. Karlsson AF, Dahlberg BA, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Copenh) 1989, 121 (Suppl. 2): 132–41.

    Google Scholar 

  48. Weetman A, Wiersinga WM. Current management of thyroid- associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998, 49: 21–8.

    Article  CAS  Google Scholar 

  49. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997, 7: 259–64.

    Article  PubMed  CAS  Google Scholar 

  50. DeGroot LJ, Benjasuratwong Y. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves’ disease. Orbit 1996, 15: 187–96.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, Division of Endocrinology, University of Insubria, Ospedale di Circolo, Viale Borri, 57, 21100, Varese, Italy

    L. Bartalena, M. L. Tanda, E. Piantanida & A. Lai

  2. Department of Endocrinology, University of Pisa, Pisa, Italy

    A. Pinchera

Authors
  1. L. Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Piantanida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Pinchera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartalena, L., Tanda, M.L., Piantanida, E. et al. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 27, 288–294 (2004). https://doi.org/10.1007/BF03345279

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345279

Key-words

Search

Navigation